MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 22 2024
0mins
Source: businesswire
Company Rebranding: TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, has announced its rebranding and will begin trading under the new stock symbol "TNFA" on July 24, 2024, reflecting its focus on developing therapies targeting TNF-alpha related diseases.
Clinical Development of MYMD-1: The company is advancing mid-stage clinical trials for its lead drug candidate, MYMD-1, an oral TNF-alpha inhibitor aimed at treating sarcopenia and other autoimmune and inflammatory conditions, following positive results from a Phase 2 study.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
